Praxis Precision Medicines (NASDAQ:PRAX) Stock Acquired by Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Rep. Gilbert Ray Cisneros Jr. purchased $1,001–$15,000 of Praxis Precision Medicines stock on September 29, according to a congressional disclosure filed October 12.
• Praxis shares opened at $243.34, with a $6.79 billion market capitalization and a 52-week range of $50.56 to $392.70. The company recently reported a quarterly loss of $2.87 per share, beating analyst estimates.
• Wall Street maintains a generally bullish outlook, with a consensus “Moderate Buy” rating and an average price target of $613.26, although one firm rates the stock a sell. Institutional investors own 67.84% of the company.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Praxis Precision Medicines stock on September 29th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Benchmark Electronics NYSE: BHE on 10/1/2026.
• Sold $1,001 - $15,000 in shares of Oxford Industries NYSE: OXM on 9/29/2026.
• Sold $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 9/29/2026.
• Sold $15,001 - $50,000 in shares of ITT NYSE: ITT on 9/29/2026.
• Sold $1,001 - $15,000 in shares of BridgeBio Pharma NASDAQ: BBIO on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Tandem Diabetes Care NASDAQ: TNDM on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Cytokinetics NASDAQ: CYTK on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Ultragenyx Pharmaceutical NASDAQ: RARE on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of YETI NYSE: YETI on 9/29/2026.
• Sold $1,001 - $15,000 in shares of AtriCure NASDAQ: ATRC on 9/29/2026.

Praxis Precision Medicines Stock Performance

Praxis Precision Medicines stock opened at $243.34 on Wednesday. The firm has a market cap of $6.79 billion, a P/E ratio of -18.82 and a beta of 2.79. The business's fifty day moving average is $328.11 and its two-hundred day moving average is $319.59. Praxis Precision Medicines, Inc. has a 52 week low of $50.56 and a 52 week high of $392.70.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($2.87) earnings per share for the quarter, beating analysts' consensus estimates of ($3.67) by $0.80. On average, equities research analysts predict that Praxis Precision Medicines, Inc. will post -13.90 earnings per share for the current year.

Hedge Funds Weigh In On Praxis Precision Medicines

A number of hedge funds and other institutional investors have recently bought and sold shares of PRAX. Avior Wealth Management LLC acquired a new position in shares of Praxis Precision Medicines in the 3rd quarter valued at $227,000. GAMMA Investing LLC boosted its position in shares of Praxis Precision Medicines by 30.1% in the 3rd quarter. GAMMA Investing LLC now owns 432 shares of the company's stock worth $126,000 after purchasing an additional 100 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of Praxis Precision Medicines in the 2nd quarter worth $38,000. Nykredit A S bought a new position in shares of Praxis Precision Medicines in the 2nd quarter worth $261,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Praxis Precision Medicines during the second quarter worth $2,698,000. 67.84% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on PRAX. The Goldman Sachs Group reissued a "buy" rating and issued a $575.00 price target (up from $470.00) on shares of Praxis Precision Medicines in a report on Friday, August 21st. Wells Fargo & Company reaffirmed a "positive" rating and set a $362.00 price objective (up from $323.00) on shares of Praxis Precision Medicines in a report on Friday, August 7th. Piper Sandler reaffirmed an "overweight" rating on shares of Praxis Precision Medicines in a report on Monday, July 13th. Robert W. Baird set a $514.00 price target on Praxis Precision Medicines in a research note on Friday, August 7th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Praxis Precision Medicines in a research note on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $613.26.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. The company uses insights from human genetics, neuroscience and its Cerebrum™ platform to identify and advance medicines for conditions in which existing treatment options may be limited.

Praxis' pipeline has included investigational treatments for epilepsies and other neurological disorders, including developmental and epileptic encephalopathies, essential tremor and movement-related conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.